Compound Evidence File
#EC-2026-0496
Methylstenbolone
Filed under Oral Tablets. The bureau holds 130 laboratory returns for this compound from 39 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
39 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 5 Jan 2026 | 25 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 28 Apr 2026 | 27 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Dec 2025 | 1 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 13 Feb 2026 | 9 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 22 Jan 2026 | 28 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Apr 2026 | 11 Aug 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 16 Apr 2026 | 22 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Apr 2026 | 7 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Jun 2026 | 13 Aug 2026 |
| Pura PeptidesCASE #VI-2026-0307 | X | 1 | 10.0 | 10.0 | 10.0 | 21 May 2025 | 21 May 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Jun 2026 | 11 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Apr 2026 | 11 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 5 Feb 2026 | 13 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 14 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 9.9 | 10 Mar 2026 | 11 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Jan 2026 | 6 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 9.9 | 9.9 | 9.9 | 14 Jan 2026 | 3 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 9.9 | 2 Apr 2026 | 10 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 21 Jun 2026 | 4 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 5 Jul 2026 | 6 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 9.9 | 15 Mar 2026 | 6 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Jun 2026 | 9 Jun 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 9.1 | 8.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.5 | 7.4 | 9.4 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.5 | 7.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.1 | 7.0 | 9.5 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 7.9 | 6.0 | 9.4 | 24 May 2026 | 24 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 2 | 7.7 | 6.6 | 8.8 | 24 Apr 2025 | 25 May 2026 |
| TCICASE #VI-2026-0650 | X | 1 | 7.7 | 7.7 | 7.7 | 13 Jun 2025 | 13 Jun 2025 |
| NexaphCASE #VI-2026-0944 | X | 9 | 7.5 | 4.0 | 9.3 | 2 Jul 2025 | 20 May 2026 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 7.3 | 7.3 | 7.3 | 6 May 2025 | 6 May 2025 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 7.1 | 7.1 | 7.1 | 17 Dec 2024 | 17 Dec 2024 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 6.8 | 6.8 | 6.8 | 16 Mar 2025 | 16 Mar 2025 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 2 | 6.5 | 5.9 | 7.1 | 8 Jul 2025 | 21 May 2026 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 2 | 6.5 | 6.3 | 6.8 | 28 Mar 2025 | 19 Jan 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 2 | 5.6 | 3.2 | 7.9 | 9 Jun 2025 | 21 May 2026 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 5.2 | 5.2 | 5.2 | 28 Mar 2025 | 28 Mar 2025 |
Open any subject to view the batch-level evidence for Methylstenbolone alone.